A new cervical cancer treatment is showing promise in boosting survival rates and reducing recurrence What this breakthrough means for patients.

Cervical cancer is caused by human papillomavirus HPV and has become a major health concern Read this article to know ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

Joining a clinical trial for cervical cancer opens the door to new treatments that could have life-changing effects.

One of the key findings in recent studies is the superior diagnostic capability of FDG PET-CT compared to MRI in detecting recurrent cervical cancer after radiotherapy. A study showed that FDG PET ...

Chemoradiation with platinum-based chemo is standard for locally advanced cervical cancer, but adverse events drive ...

Health experts estimate that nearly 14,000 women in the U.S. will be diagnosed with cervical cancer, with more than 4,000 ...

Many of the annual cervical cancer cases originate in countries ... to be certain none of the abnormal cells were missed or are recurrent. Dr. Kerry Hudson is an OB-GYN physician, Estefany Flores ...

In Europe, meanwhile, Regeneron’s PD-1 inhibitor Libtayo (cemiplimab) is indicated as a second-line therapy for recurrent or advanced cervical cancer, regardless of PD-L1 expression status, ...

Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...